COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
Defence Therapeutics Inc. announces successful inhibition of ovarian cancer growth with ARM-X anti-cancer vaccine and anti-PD-1 combination therapy in pre-established cancer models -
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Signature d’un contrat de cession d’actions pour l’acquisition d’une participation majoritaire dans Neoen par Brookfield auprès d’Impala et d’autres actionnaires, et d’un engagement d’apport entre Brookfield et Bpifrance
Signature d'un contrat de cession d'actions pour l'acquisition d'une participation majoritaire dans Neoen par Brookfield auprès d'Impala et d'autres actionnaires, et d'un engagement d'apport entre Brookfield et Bpifrance. Acquisition du Bloc soumise aux autorisations réglementaires. Brookfield lancera une offre publique d'achat obligatoire en numéraire -
COMMUNIQUÉ RÉGLEMENTÉ
Signing of the share purchase agreement for the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders and of a tender agreement between Brookfield and Bpifrance
Brookfield signs share purchase agreement with Neoen for majority stake acquisition. Tender agreement with Bpifrance signed. Expected regulatory approvals in Q4 2024. Tender offer in Q1 2025 -
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
Schneider Electric launches €750 million Bonds offering convertible into new shares and/or exchangeable for existing shares, along with a repurchase of outstanding OCEANEs. Details of the transaction, terms, and conditions provided
